HK StockDetailed Quotes

Provided by Tiger Fintech (Singapore) Pte. Ltd.

Aesthetic Medicine

1,383.670

+24.7271.82%

Number of Gainers:6

Number of Losers:4

Number of Flat:3

PE:- -

High:1,391.276

Open:1,338.916

Low:1,336.002

Close:1,358.943

Volume:46.93M

Turnover:1.20B

Market Cap:223.25B

Float Cap:168.64B

Loading ...

HK Movers｜3SBIO Rises 8% in Early Trading as Pfizer Initiates Two Global Phase III Trials for SSGJ-707

HK Stock Buyback Summary | October 31

CMS (00867): China's NMPA Accepts Marketing Application for Long-Acting Anti-IL-4Rα Monoclonal Antibody for Atopic Dermatitis

China Medical System Gets NMPA Acceptance for Atopic Dermatitis Drug Application

China Medical System - Nda for Atopic Dermatitis Indication of Long-Acting Anti-Il-4Ra Humanized Monoclonal Antibody Injection Accepted in China

THOMSON REUTERS

HAOHAI BIOTEC (06826) Repurchased 27,500 Shares for Approximately HK$745,300 on October 30

SIHUAN PHARM Surges Over 4% in Early Trading After Signing Collaboration Agreement with U.S.'s AbaloneBio

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www-web.itiger.com/stock/BK1593/news?page=3"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"BK1593","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"BK1593\",,,,,undefined,":{"symbol":"BK1593","market":"HK","secType":"PLATE","nameCN":"Aesthetic Medicine","latestPrice":1383.6698,"timestamp":1763091119542,"preClose":1358.9427,"halted":0,"volume":46934513,"delay":0,"changeRate":0.018196,"floatShares":0,"shares":0,"eps":0,"marketStatus":"Trading","change":24.727051,"latestTime":"11-14 11:32:01","open":1338.9164,"high":1391.2762,"low":1336.0016,"amount":1200392175,"amplitude":0.040675,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"tradingStatus":0,"nextMarketStatus":{"tag":"Noon Closed","tradingStatus":4,"beginTime":1763092800000},"marketStatusCode":0,"adr":0,"adjPreClose":0,"openAndCloseTimeList":[[1763083800000,1763092800000],[1763096400000,1763107200000]],"pbRate":1.930004,"peRate":27.695042,"turnoverRate":0.002357,"increases":6,"decrements":4,"flats":3,"marketCap":223249254104,"floatMarketCap":168635758936},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"BK1593\",,,,,undefined,":{"symbol":"BK1593","high":1391.2762,"amplitude":0.040675,"preClose":1358.9427,"low":1336.0016,"pbRate":"1.930004","latestPrice":1383.6698,"volume":46934513,"delay":0,"open":1338.9164,"prevYearClose":571.87146,"prevWeekClose":1251.598,"prevMonthClose":1288.46,"prevQuarterClose":1308.644,"fiveDayClose":1251.598,"twentyDayClose":1265.195,"sixtyDayClose":1321.541,"secType":"PLATE","market":"HK","turnoverRate":0.002357,"peRate":27.695042,"marketCap":223249254104,"floatMarketCap":168635758936,"timestamp":1763091119542,"nameCN":"Aesthetic Medicine"},"@#url:\"https://hq.skytigris.cn/api/global/plate/up_down\",method:\"POST\",data:#delay:false,bkCodes:@\"BK1593\",,,,undefined,":{"bkCode":"BK1593","up":6,"down":4,"flat":3},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"BK1593\",pageSize:20,pageCount:3,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"1185000236","title":"HK Movers｜3SBIO Rises 8% in Early Trading as Pfizer Initiates Two Global Phase III Trials for SSGJ-707","url":"https://stock-news.laohu8.com/highlight/detail?id=1185000236","media":"Stock News","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1185000236?lang=en_us&edition=fundamental","pubTime":"2025-10-31 09:50","pubTimestamp":1761875407,"startTime":"0","endTime":"0","summary":"3SBIO (01530) surged nearly 7% in early trading, reaching HK$29.46 with a turnover of HK$381 million by the time of reporting. The uptick follows news that Pfizer (PFE) registered two global Phase...","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"a08235b539b1acf257c7ed4f00bf392e","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":true,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE00B19Z3581.USD","BK1161","BK4550","SG9999003800.SGD","BK4534","IE00B19Z3B42.SGD","LU1883839398.USD","LU1023059063.AUD","PFE","LU0306807586.USD","LU0321505439.SGD","LU1066053197.SGD","IE00BLSP4239.USD","BK4568","BK4581","LU0170899867.USD","IE000M9KFDE8.USD","SG9999001176.USD","SG9999002224.SGD","LU0234572021.USD","LU0456855351.SGD","IE00BLSP4452.SGD","LU0868494617.USD","LU1894683264.USD","BK1593","LU0306806265.USD","LU0321505868.SGD","BK1583","BK4007","BK4588","SG9999001176.SGD","LU0225771236.USD","01530","LU0985481810.HKD","SG9999002232.USD","LU1057294990.SGD","LU1894683348.USD","SG9999011175.SGD","IE0002270589.USD","IE00BBT3K403.USD","BK4599","LU0225284248.USD","BK4585","LU1066051498.USD","LU0122379950.USD","SGXZ57979304.SGD","BK4533","SG9999013999.USD","LU0289739699.SGD","BK4592","LU0058720904.USD"],"gpt_icon":0},{"id":"1197902130","title":"HK Stock Buyback Summary | October 31","url":"https://stock-news.laohu8.com/highlight/detail?id=1197902130","media":"Stock News","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1197902130?lang=en_us&edition=fundamental","pubTime":"2025-10-31 09:12","pubTimestamp":1761873166,"startTime":"0","endTime":"0","summary":"On October 30, 2025, multiple Hong Kong-listed companies conducted share buybacks. Among them, China Feihe (06186) executed the largest buyback, repurchasing 12 million shares for HKD 50.23 million....","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1170","02486","LU1188198961.HKD","BK1506","LU0650527681.SGD","BK1521","LU0463099449.HKD","LU1224709979.USD","LU1439103000.SGD","06186","BK1575","HK0000320223.HKD","LU0823426480.USD","LU0029875118.USD","LU0672654166.SGD","LU0211977185.USD","BK1528","LU1831875114.USD","BK1562","LU0140636845.USD","LU1023057109.AUD","BK1109","LU0359201885.HKD","LU0293314216.USD","BK1253","02190","BK1599","LU0251143458.SGD","BK1516","06098","BK1574","BK1500","BK1618","LU0106959298.USD","00909","LU0823426308.USD","BK1137","BK1226","BK1201","06826","LU0828237940.HKD","LU1051769294.HKD","01497","LU2460026573.USD","LU0163747925.USD","IE00B031HY20.USD","LU0348805143.USD","00386","BK1589","BK1160","LU0543330483.HKD","LU0588546209.SGD","IE00B067MR52.USD","LU0315179316.USD","BK1158","BK1237","HK0000306685.HKD","LU0370786039.SGD","LU2097828805.USD","SG9999011746.SGD","LU0359202008.SGD","BK1229","LU0651947912.USD","02120","HK0000320264.USD","IE0008369823.USD","02319","BK1593","00418","LU0307460666.USD","LU0326950275.SGD","BK1258","LU2125910500.SGD","IE00B031J352.USD","LU0228659784.USD","LU1282651048.USD","00947","BK1553","02142","BK1100","LU1769817179.HKD","IE0032834883.USD","BK1549","BK1117","IE00B97KM107.HKD","LU0594300419.USD","IE00B29SXG58.USD","02869","02273","01167","01373","BK1149","BK1597","00103","LU0821914370.USD","LU2097828557.USD","IE0031814852.USD","LU1102505929.USD","BK1161","BK1583","LU0259732245.USD","01681","LU0359201612.USD","BK1155","LU0737861699.HKD","LU1048588211.SGD","LU0287142896.SGD","LU2045819591.USD","LU1051768304.USD","SG9999002828.SGD","02005","LU0651946864.USD","01583","08128","BK1151","LU0328353924.USD","09959","02416","IE00B0169L03.USD","00732","02598","BK1219","LU2097828714.EUR","BK1518","IE0008368742.USD","06868","LU0072462343.USD","LU0228367735.SGD","BK1209","BK1225","LU0320764755.SGD","LU0385154629.USD","HK0000306701.USD","LU2097828474.EUR","LU0244354667.USD","LU2097828631.EUR","01519","LU0181495838.USD","BK1587","LU0471298777.SGD","LU0048580855.USD","BK1607","LU0128522157.USD","LU1048596156.SGD","LU1102505762.USD","BK1619","LU0348788117.USD","LU1515016050.SGD","LU1769817096.USD","LU0173614495.USD","IE0009570106.USD","BK1191","02299","BK1542","09890","BK1606"],"gpt_icon":0},{"id":"1146671574","title":"CMS (00867): China's NMPA Accepts Marketing Application for Long-Acting Anti-IL-4Rα Monoclonal Antibody for Atopic Dermatitis","url":"https://stock-news.laohu8.com/highlight/detail?id=1146671574","media":"Stock News","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1146671574?lang=en_us&edition=fundamental","pubTime":"2025-10-30 18:56","pubTimestamp":1761821800,"startTime":"0","endTime":"0","summary":"CMS (00867) announced that the marketing authorization application (MAA) for its innovative Class 1 new drug, anti-IL-4Rα humanized monoclonal antibody injection MG-K10 (generic name: Komeqimab...","market":"sg","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE00BVYPNQ40.USD","LU2488822045.USD","IE00BVYPNP33.GBP","IE00BYV24P56.USD","SG9999015952.SGD","SG9999004220.SGD","SG9999015986.USD","SG9999015978.USD","IE00BMCWC346.EUR","BK1191","BK1593","00867","SG9999015945.SGD","IE00BGHQDM52.EUR"],"gpt_icon":0},{"id":"2579192231","title":"China Medical System Gets NMPA Acceptance for Atopic Dermatitis Drug Application","url":"https://stock-news.laohu8.com/highlight/detail?id=2579192231","media":"Reuters","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2579192231?lang=en_us&edition=fundamental","pubTime":"2025-10-30 18:19","pubTimestamp":1761819554,"startTime":"0","endTime":"0","summary":"China Medical System Holdings Limited announced that its subsidiary, Dermavon Holdings Limited, has had its Marketing Authorization Application for Comekibart Injection , a long-acting anti-IL-4Rα humanized monoclonal antibody injection, accepted by China's National Medical Products Administration . The product is intended for the treatment of adults with moderate-to-severe atopic dermatitis. The announcement marks the beginning of the regulatory review process for this innovative drug in China. There is no indication that grant funding was obtained or that the regulatory review involves organizations other than China Medical System Holdings Limited and its subsidiaries.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. China Medical Syst","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251030:nNDL7zkqhB:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1191","SG9999015978.USD","SG9999015986.USD","IE00BVYPNQ40.USD","SG9999015952.SGD","00867","IE00BYV24P56.USD","LU2488822045.USD","BK1593","IE00BVYPNP33.GBP","IE00BGHQDM52.EUR","SG9999015945.SGD","SG9999004220.SGD","IE00BMCWC346.EUR"],"gpt_icon":0},{"id":"2579119391","title":"China Medical System  - Nda for Atopic Dermatitis Indication of Long-Acting Anti-Il-4Ra Humanized Monoclonal Antibody Injection Accepted in China","url":"https://stock-news.laohu8.com/highlight/detail?id=2579119391","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2579119391?lang=en_us&edition=fundamental","pubTime":"2025-10-30 18:15","pubTimestamp":1761819310,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251030:nFWN3WB0YL:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["00867","IE00BVYPNP33.GBP","IE00BMCWC346.EUR","SG9999004220.SGD","BK1191","IE00BYV24P56.USD","LU2488822045.USD","IE00BVYPNQ40.USD","SG9999015952.SGD","SG9999015986.USD","SG9999015945.SGD","SG9999015978.USD","IE00BGHQDM52.EUR","BK1593"],"gpt_icon":0},{"id":"1166700880","title":"HAOHAI BIOTEC (06826) Repurchased 27,500 Shares for Approximately HK$745,300 on October 30","url":"https://stock-news.laohu8.com/highlight/detail?id=1166700880","media":"Stock News","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1166700880?lang=en_us&edition=fundamental","pubTime":"2025-10-30 17:46","pubTimestamp":1761817573,"startTime":"0","endTime":"0","summary":"HAOHAI BIOTEC (06826) announced that on October 30, 2025, the company repurchased 27,500 shares at a total cost of approximately HK$745,300.","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1593","06826","BK1161"],"gpt_icon":0},{"id":"1158632927","title":"SIHUAN PHARM Surges Over 4% in Early Trading After Signing Collaboration Agreement with U.S.'s AbaloneBio","url":"https://stock-news.laohu8.com/highlight/detail?id=1158632927","media":"Deep News","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1158632927?lang=en_us&edition=fundamental","pubTime":"2025-10-30 11:20","pubTimestamp":1761794439,"startTime":"0","endTime":"0","summary":"SIHUAN PHARM (00460) rose more than 4% in early trading, with shares up 4.11% to HKD 1.52 at the time of writing, recording a turnover of HKD 57.79 million. On October 30, SIHUAN PHARM announced that...","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["00460","BK1515","BK1191","BK1600","BK1593"],"gpt_icon":0}],"pageSize":20,"totalPage":3,"pageCount":3,"totalSize":47,"code":"91000000","status":"200"}]}}